Robert H. Vonderheide, MD, DPhil, director of Abramson Cancer Center at Penn, is spearheading a phase 1 study designed to assess whether the addition of the anti-CD40 drug selicrelumab (RO7009789, Roche) to nab-paclitaxel (Abraxane, Celgene) and gemcitabine in the presurgical and postsurgical settings is safe and effective for pancreatic cancer treatment. Read more . . .
Researchers at University of Pennsylvania are investigating anti-CD40 antibodies in a number of combinations in pancreatic cancer and other malignancies in which the baseline line immune response against the tumor is insufficient.